Related Experiment Video
Updated: Sep 28, 2025

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry
Meryl Waldman1, Maria Jose Soler2,3, Clara García-Carro2,3
1Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Insights
COVID-19 infection did not increase mortality or acute kidney injury (AKI) in glomerulonephritis (GN) patients. However, GN patients face higher risks of impaired kidney function recovery after COVID-19-associated AKI.
Area of Science:
- Nephrology
- Infectious Diseases
- Critical Care Medicine
Background:
- The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on individuals with glomerulonephritis (GN) remains incompletely understood.
- The International Registry of COVID-19 infection in GN was established to investigate these effects.
Purpose of the Study:
- To evaluate the acute and long-term effects of COVID-19 on patients with GN.
- To compare outcomes between GN patients and non-GN controls following SARS-CoV-2 infection.
Main Methods:
- Serial data on kidney-related and unrelated outcomes were collected from 125 GN patients and 83 non-GN controls with COVID-19.
- Follow-up duration was a median of 6.4 months post-diagnosis.
- Logistic regression and linear mixed models were used for outcome and eGFR analyses, adjusted for confounders.
Main Results:
- No significant differences in mortality or acute kidney injury (AKI) were observed between GN patients and controls after adjusting for pre-COVID-19 eGFR and other factors.
- Pre-COVID-19 eGFR was the primary predictor of AKI (aOR per 1 SD decrease = 3.04, P<0.001).
- GN patients with COVID-19-associated AKI showed significantly lower eGFR recovery at 6 months compared to controls (aOR=0.41). Factors like shorter GN duration, higher proteinuria, and specific diagnoses (FSGS, MCD) were linked to poorer eGFR recovery.
Conclusions:
- Baseline eGFR is the key risk factor for AKI in COVID-19, irrespective of GN diagnosis.
- Glomerulonephritis patients exhibit a heightened risk of impaired eGFR recovery post-COVID-19-associated AKI.
- Close monitoring of GN patients, particularly those with high proteinuria or diagnoses of FSGS/MCD, is crucial during and after acute COVID-19 illness.
Background:
The acute and long-term effects of severe acute respiratory syndrome coronavirus 2 infection in individuals with GN are still unclear. To address this relevant issue, we created the International Registry of COVID-19 infection in GN.
Methods:
We collected serial information on kidney-related and -unrelated outcomes from 125 GN patients (63 hospitalized and 62 outpatients) and 83 non-GN hospitalized patients with coronavirus disease 2019 (COVID-19) and a median follow-up period of 6.4 (interquartile range 2.3-9.6) months after diagnosis. We used logistic regression for the analyses of clinical outcomes and linear mixed models for the longitudinal analyses of eGFR. All multiple regression models were adjusted for age, sex, ethnicity, and renin-angiotensin-aldosterone system inhibitor use.
Results:
After adjustment for pre-COVID-19 eGFR and other confounders, mortality and AKI did not differ between GN patients and controls (adjusted odds ratio for AKI=1.28; 95% confidence interval [CI], 0.46 to 3.60; P=0.64). The main predictor of AKI was pre-COVID-19 eGFR (adjusted odds ratio per 1 SD unit decrease in eGFR=3.04; 95% CI, 1.76 to 5.28; P<0.001). GN patients developing AKI were less likely to recover pre-COVID-19 eGFR compared with controls (adjusted 6-month post-COVID-19 eGFR=0.41; 95% CI, 0.25 to 0.56; times pre-COVID-19 eGFR). Shorter duration of GN diagnosis, higher pre-COVID-19 proteinuria, and diagnosis of focal segmental glomerulosclerosis or minimal change disease were associated with a lower post-COVID-19 eGFR.
Conclusions:
Pre-COVID-19 eGFR is the main risk factor for AKI regardless of GN diagnosis. However, GN patients are at higher risk of impaired eGFR recovery after COVID-19-associated AKI. These patients (especially those with high baseline proteinuria or a diagnosis of focal segmental glomerulosclerosis or minimal change disease) should be closely monitored not only during the acute phases of COVID-19 but also after its resolution.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Chronic Kidney Disease I: Introduction
Acute Kidney Injury II: Pathophysiology

